Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Domachowske J, et al. Among authors: furuno k. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. N Engl J Med. 2022. PMID: 35235733 Clinical Trial. No abstract available.
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
Domachowske JB, Chang Y, Atanasova V, Cabañas F, Furuno K, Nguyen KA, Banu I, Kubiak RJ, Leach A, Mankad VS, Shroff M, Takas T, Villafana T, Wählby Hamrén U. Domachowske JB, et al. Among authors: furuno k. J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052. J Pediatric Infect Dis Soc. 2023. PMID: 37466917 Free PMC article.
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
Tuffy KM, Ahani B, Domachowske JB, Furuno K, Ji H, Madhi SA, Mankad VS, Hamrén UW, Villafana T, Wang Y, Kelly EJ, Wilkins D. Tuffy KM, et al. Among authors: furuno k. Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241352 Free article. Clinical Trial.
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Oey A, McClure M, Symons JA, Chanda S, Fry J, Smith PF, Luciani K, Fayon M, Chokephaibulkit K, Uppala R, Bernatoniene J, Furuno K, Stanley T, Huntjens D, Witek J; 503 and RSV2004 Study Groups. Oey A, et al. Among authors: furuno k. PLoS One. 2023 Jul 19;18(7):e0288271. doi: 10.1371/journal.pone.0288271. eCollection 2023. PLoS One. 2023. PMID: 37467213 Free PMC article. Clinical Trial.
Regression effect of renin-angiotensin-aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study.
Suganuma E, Miura M, Koyama Y, Kobayashi T, Kaneko T, Hokosaki T, Numano F, Furuno K, Shiono J, Fuse S, Fukazawa R, Mitani Y. Suganuma E, et al. Among authors: furuno k. Eur J Pediatr. 2024 Nov;183(11):4817-4825. doi: 10.1007/s00431-024-05765-3. Epub 2024 Sep 6. Eur J Pediatr. 2024. PMID: 39240388
Respiratory viral infections and Kawasaki disease: A molecular epidemiological analysis.
Marutani K, Murata K, Mizuno Y, Onoyama S, Hoshina T, Yamamura K, Furuno K, Sakai Y, Kishimoto J, Kusuhura K, Hara T. Marutani K, et al. Among authors: furuno k. J Microbiol Immunol Infect. 2024 Oct;57(5):691-699. doi: 10.1016/j.jmii.2024.07.001. Epub 2024 Jul 14. J Microbiol Immunol Infect. 2024. PMID: 39034166 Free article.
Evolutionary dynamics of the novel ST22-PT methicillin-resistant Staphylococcus aureus clone co-harbouring Panton-Valentine leucocidin and duplicated toxic shock syndrome toxin 1 genes.
Yamaguchi T, Furuno K, Komori K, Abe T, Sato T, Ogihara S, Aoki K, Ishii Y, Tateda K. Yamaguchi T, et al. Among authors: furuno k. Clin Microbiol Infect. 2024 Jun;30(6):779-786. doi: 10.1016/j.cmi.2024.02.020. Epub 2024 Feb 24. Clin Microbiol Infect. 2024. PMID: 38408643 Free article.
Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Kawabe T, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, Nishikomori R; Japan CAPS Working Group. Miyamoto T, et al. Among authors: furuno k. Arthritis Rheumatol. 2024 Jun;76(6):949-962. doi: 10.1002/art.42808. Epub 2024 Mar 7. Arthritis Rheumatol. 2024. PMID: 38268504
CD14 down-modulation as a real-time biomarker in Kawasaki disease.
Inada Y, Sonoda M, Mizuno Y, Yamamura K, Motomura Y, Takuma A, Murata K, Furuno K, Tezuka J, Sakai Y, Ohga S, Kishimoto J, Hosaka K, Sakata S, Hara T. Inada Y, et al. Among authors: furuno k. Clin Transl Immunology. 2023 Dec 30;13(1):e1482. doi: 10.1002/cti2.1482. eCollection 2024. Clin Transl Immunology. 2023. PMID: 38162960 Free PMC article.
231 results